Related Experiment Video
Updated: Jul 2, 2025
07:32
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.3K
Prognostic Value of the Lung Immune Prognostic Index on Recurrence after Radical Surgery for High-Risk Renal Cell
Yudai Ishiyama1,2, Tsunenori Kondo3, Kazuhiko Yoshida1
1Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan.
Cancers
|February 24, 2024
Summary
The Lung Immune Prognostic Index (LIPI) effectively predicts recurrence in high-risk renal cell carcinoma (hrRCC) patients post-surgery. This index aids in identifying patients with the highest risk for recurrence, informing treatment decisions.
Area of Science:
- Oncology
- Immunology
- Biomarker Research
Background:
- Adjuvant immunotherapy options are emerging for high-risk renal cell carcinoma (hrRCC).
- Further risk stratification is crucial for optimizing treatment decisions in hrRCC patients.
- The Lung Immune Prognostic Index (LIPI) has shown prognostic value in various cancers.
Purpose of the Study:
- To evaluate the prognostic value of the Lung Immune Prognostic Index (LIPI) in patients with high-risk renal cell carcinoma (hrRCC) undergoing radical surgery.
- To assess the association between LIPI scores and recurrence-free survival (RFS) in hrRCC.
- To determine if LIPI can independently predict RFS and improve existing staging systems.
Main Methods:
- A retrospective analysis of 235 patients with hrRCC who underwent radical surgery (2004-2021).
- LIPI scores were calculated using neutrophil-to-lymphocyte ratio and lactate dehydrogenase levels.
- Statistical analysis, including multivariate modeling and C-index calculation, was used to assess LIPI's predictive accuracy for RFS.
Main Results:
- LIPI scores significantly correlated with recurrence-free survival (RFS).
- Patients in the poor LIPI group had significantly lower RFS rates compared to good and intermediate groups.
- LIPI independently predicted RFS and improved the predictive accuracy when added to established staging systems (e.g., UCLA ISS).
Conclusions:
- The Lung Immune Prognostic Index (LIPI) is a significant prognostic biomarker for predicting recurrence in high-risk renal cell carcinoma (hrRCC).
- LIPI is particularly valuable for identifying the highest-risk patient cohort, aiding in clinical decision-making.
- Incorporating LIPI into risk stratification models can enhance prognostic accuracy for hrRCC recurrence.
